Unusual Adverse Events in a Patient With BRAF-Mutated Non-Small Cell Lung Cancer Treated With BRAF/MEK Inhibition

Area of Science:

• Oncology
• Pharmacology
• Dermatology

Background:

• BRAF/MEK inhibition is standard for BRAF-mutated non-small cell lung cancer (NSCLC).
• Uncommon adverse events (AEs) of these targeted therapies are infrequently reported.
• Recognition of unusual AEs is crucial for continued treatment.

Purpose of the Study:

• To report a case of unusual AEs in a patient with BRAF-mutated NSCLC treated with dabrafenib and trametinib.
• To highlight the successful management of these AEs and continuation of targeted therapy.
• To emphasize the importance of recognizing rare AEs associated with BRAF/MEK inhibition.

Main Methods:

• Case report of a patient with BRAF-mutated NSCLC.
• Documentation of unusual adverse events: Sweet syndrome and MEK-associated retinopathy.
• Treatment with corticosteroids and multidisciplinary care coordination.

Main Results:

• The patient experienced Sweet syndrome and MEK-associated retinopathy during dabrafenib and trametinib treatment.
• These unusual AEs responded well to systemic steroid therapy.
• The patient successfully continued BRAF/MEK inhibition with dose adjustments and supportive care.

Conclusions:

• Sweet syndrome and MEK-associated retinopathy are rare but manageable AEs of BRAF/MEK inhibitors.
• Prompt recognition and steroid treatment facilitate continued targeted therapy in NSCLC.
• Clinicians should be vigilant for unusual AEs, especially with expanding indications for BRAF/MEK inhibitors.